DTIL
Precision BioSciences, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Neutral
-18/100
Last price
6.20
▼ 0.11 (1.74%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
6.50
Prev close
6.31
Day high
6.40
Day low
6.11
Volume
190.96K
Market cap
$171.13M
P/E (TTM)
—
52W range
3.53 – 9.62
Day trading desk
Gap from prior close
+3.01%
Prior close 6.31
VWAP
6.24
-0.63% from price
Relative volume
0.59×
Quiet session
Session range
6.47%
6.11 – 6.50
Position in range
24%
Near session low
ATR (14D)
0.39
6.33% of price
Prior day high
6.38
PDH
Prior day low
5.97
PDL
Bid / ask spread
—
Quote not published
Session volume
181.91K
Avg 308.85K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+0.32%
-1.6%
1M
-17.00%
-18.2%
3M
-33.19%
-37.7%
6M
-0.96%
-19.1%
YTD
+49.04%
+34.8%
1Y
+13.97%
-2.4%
3Y
-39.39%
-121.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on DTIL open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
2.22M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 28, 26 | FRANKEL STANLEY R. Director |
BUY | 1.00K | $6.00K | Direct |
| Sep 25, 26 | GERMANO GENO J Director |
BUY | 2.61K | $16.39K | Direct |
| Sep 25, 26 | BROWN MELINDA Director |
BUY | 1.14K | $7.12K | Direct |
| May 20, 26 | BUEHLER KEVIN Director |
— | 21.00K | — | Direct |
| May 20, 26 | GERMANO GENO J Director |
— | 21.00K | — | Direct |
| May 20, 26 | BROWN MELINDA Director |
— | 21.00K | — | Direct |
| May 20, 26 | FRANKEL STANLEY R. Director |
— | 21.00K | — | Direct |
| May 20, 26 | PIRE SHARI LISA J.D. Director |
— | 21.00K | — | Direct |
| Feb 18, 26 | KELLY JOHN ALEXANDER Chief Financial Officer |
SELL | 8.15K | $31.29K | Direct |
| Feb 18, 26 | SMITH J JEFFERSON Officer |
SELL | 4.92K | $18.91K | Direct |
| Feb 18, 26 | SCIMECA DARIO JOSEPH General Counsel |
SELL | 4.92K | $18.91K | Direct |
| Feb 18, 26 | AMOROSO MICHAEL Chief Executive Officer |
SELL | 20.56K | $78.95K | Direct |
| Feb 17, 26 | KELLY JOHN ALEXANDER Chief Financial Officer |
— | 27.58K | — | Direct |
| Feb 17, 26 | SMITH J JEFFERSON Officer |
— | 16.67K | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
AMOROSO MICHAEL |
Chief Executive Officer | 243.39K | Sale |
BROWN MELINDA |
Director | 45.48K | Purchase |
BUEHLER KEVIN |
Director | 49.14K | Conversion of Exercise of derivative security |
FRANKEL STANLEY R. |
Director | 41.48K | Purchase |
GERMANO GENO J |
Director | 47.49K | Purchase |
KELLY JOHN ALEXANDER |
Chief Financial Officer | 125.88K | Sale |
PIRE SHARI LISA J.D. |
Director | 35.03K | Conversion of Exercise of derivative security |
SCIMECA DARIO JOSEPH |
General Counsel | 56.46K | Sale |
SMITH J JEFFERSON |
Officer | 129.86K | Sale |
Fundamentals
Market cap$171.13M
Enterprise value$111.68M
Revenue (TTM)$45.05M
Gross profit$45.05M
EBITDA$-35.15M
Net income$-53.62M
EPS (TTM)$-1.32
Free cash flow$-16.25M
Total cash$87.55M
Total debt$28.10M
Book value / share$1.71
Shares outstanding27.60M
Float25.45M
Short % of float8.25%
Dividend yield0.00%
Beta (5Y)1.28
Valuation & profitability ratios
Trailing P/E—
Forward P/E-3.33
PEG ratio—
Price / sales—
Price / book3.62
EV / revenue2.48
EV / EBITDA-3.18
Gross margin100.00%
Operating margin-80.78%
Profit margin-117.04%
Return on equity-135.15%
Return on assets-19.37%
Debt / equity62.04
Current ratio12.82
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $34.26M | $68.70M | $48.73M | $25.10M | -50.1% |
| Operating revenue | $34.26M | $68.70M | $48.73M | $25.10M | -50.1% |
| Research & development | $54.17M | $59.56M | $53.38M | $46.12M | -9.0% |
| Selling, general & admin | $32.24M | $35.30M | $39.09M | $41.28M | -8.7% |
| Total operating expense | $86.41M | $94.86M | $92.46M | $87.41M | -8.9% |
| Operating income | -$52.15M | -$26.16M | -$43.74M | -$62.31M | -99.3% |
| Net interest income | $2.82M | $4.98M | $5.46M | $2.36M | -43.4% |
| Pre-tax income | -$46.61M | $7.17M | -$42.53M | -$72.91M | -750.3% |
| Net income | -$45.72M | $7.17M | -$61.32M | -$111.64M | -738.0% |
| Net income to common | -$45.72M | $7.17M | -$61.32M | -$111.64M | -738.0% |
| Basic EPS | -3.56 | 1.05 | -15.96 | -38.10 | -439.0% |
| Diluted EPS | -3.56 | 1.04 | -15.96 | -38.10 | -442.3% |
| EBIT | -$45.19M | $8.95M | -$40.30M | -$71.80M | -604.9% |
| EBITDA | -$42.43M | $13.53M | -$32.04M | -$62.79M | -413.7% |
| Basic shares | 12.83M | 6.83M | 3.84M | 2.93M | +87.7% |
| Diluted shares | 12.83M | 6.88M | 3.84M | 2.93M | +86.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $110.82M | $85.90M | $116.68M | $189.58M | — | +29.0% |
| Cash & short-term investments | $115.58M | $86.31M | $116.68M | $189.58M | — | +33.9% |
| Accounts receivable | $0 | $229.00K | $901.00K | $720.00K | — | -100.0% |
| Total current assets | $118.74M | $94.99M | $136.36M | $199.10M | — | +25.0% |
| Property, plant & equipment | $7.23M | $10.18M | $14.60M | $13.78M | — | -29.0% |
| Goodwill & intangibles | $1.17M | $622.00K | $400.00K | $731.00K | — | +87.5% |
| Total assets | $154.42M | $136.39M | $159.78M | $238.17M | — | +13.2% |
| Total current liabilities | $8.91M | $14.98M | $49.99M | $59.66M | — | -40.5% |
| Current debt | — | — | $22.41M | — | — | — |
| Long-term debt | $22.40M | $22.32M | — | $22.22M | $2.48M | +0.4% |
| Total debt | $28.81M | $30.05M | $31.27M | $24.96M | — | -4.1% |
| Total liabilities | $62.17M | $80.00M | $140.92M | $177.74M | — | -22.3% |
| Retained earnings | -$528.19M | -$482.46M | -$489.63M | -$428.31M | — | -9.5% |
| Shareholder equity | $92.25M | $56.39M | $18.86M | $60.43M | — | +63.6% |
| Working capital | $109.83M | $80.01M | $86.37M | $139.44M | — | +37.3% |
| Net tangible assets | $91.08M | $55.77M | $18.46M | $59.70M | — | +63.3% |
| Shares issued | 24.12M | 8.23M | 4.19M | 3.73M | — | +193.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$45.72M | $7.17M | -$61.32M | -$111.64M | -738.0% |
| Depreciation & amortisation | $2.75M | $4.58M | $8.26M | $9.00M | -39.9% |
| Stock-based compensation | $10.19M | $12.60M | $14.04M | $19.20M | -19.2% |
| Change in working capital | -$29.24M | -$54.00M | -$41.49M | $24.11M | +45.8% |
| Operating cash flow | -$65.84M | -$58.45M | -$84.11M | -$45.75M | -12.7% |
| Capital expenditure | -$700.00K | -$275.00K | -$2.28M | -$3.32M | -154.5% |
| Investing cash flow | -$634.00K | -$215.00K | $5.83M | -$3.32M | -194.9% |
| Financing cash flow | $95.16M | $50.45M | $5.39M | $94.98M | +88.6% |
| Free cash flow | -$66.54M | -$58.72M | -$86.39M | -$49.07M | -13.3% |
| End cash position | $137.15M | $108.47M | $116.68M | $189.58M | +26.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $10.84M | $34.20M | $13.00K | $18.00K | -100.0% |
| Operating revenue | $0 | $10.84M | $34.20M | $13.00K | $18.00K | -100.0% |
| Research & development | $12.39M | $13.11M | $14.46M | $13.35M | $12.77M | -5.5% |
| Selling, general & admin | $6.77M | $6.80M | $7.23M | $7.33M | $9.13M | -0.5% |
| Total operating expense | $19.16M | $19.91M | $21.70M | $20.68M | $21.89M | -3.8% |
| Operating income | -$19.16M | -$9.07M | $12.51M | -$20.67M | -$21.88M | -111.1% |
| Net interest income | $643.00K | $688.00K | $425.00K | $665.00K | $758.00K | -6.5% |
| Pre-tax income | -$32.65M | -$18.44M | $19.25M | -$21.77M | -$23.52M | -77.1% |
| Net income | -$32.65M | -$18.44M | $20.13M | -$21.77M | -$23.52M | -77.1% |
| Net income to common | -$32.65M | -$18.44M | $20.13M | -$21.77M | -$23.52M | -77.1% |
| Basic EPS | -1.26 | -0.75 | 1.06 | -1.84 | -2.13 | -68.0% |
| Diluted EPS | -1.26 | -0.75 | 1.05 | -1.84 | -2.13 | -68.0% |
| EBIT | -$32.35M | -$18.13M | $19.60M | -$21.41M | -$23.16M | -78.4% |
| EBITDA | -$31.75M | -$17.49M | $20.27M | -$20.74M | -$22.47M | -81.5% |
| Basic shares | 25.86M | 24.63M | 19.05M | 11.82M | 11.05M | +5.0% |
| Diluted shares | 25.86M | 24.63M | 19.17M | 11.82M | 11.05M | +5.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $86.08M | $99.37M | $110.82M | $44.87M | $62.24M | — | -13.4% |
| Cash & short-term investments | $87.55M | $99.37M | $115.58M | $44.87M | $62.24M | — | -11.9% |
| Accounts receivable | $0 | $4.00M | $0 | $4.00K | $0 | — | -100.0% |
| Total current assets | $91.55M | $108.69M | $118.74M | $51.70M | $70.26M | — | -15.8% |
| Property, plant & equipment | $6.08M | — | $7.23M | $8.16M | $8.82M | $9.50M | — |
| Goodwill & intangibles | $1.09M | $1.13M | $1.17M | $985.00K | $605.00K | — | -3.0% |
| Total assets | $125.92M | $143.89M | $154.42M | $93.51M | $108.93M | — | -12.5% |
| Total current liabilities | $7.14M | $7.75M | $8.91M | $15.00M | $13.57M | — | -7.9% |
| Long-term debt | $22.42M | — | $22.40M | $22.37M | $22.35M | $22.34M | — |
| Total debt | $28.10M | $6.05M | $28.81M | $29.13M | $29.45M | — | +364.7% |
| Total liabilities | $80.63M | $67.79M | $62.17M | $76.88M | $74.87M | — | +18.9% |
| Retained earnings | -$579.28M | -$546.63M | -$528.19M | -$548.32M | -$526.55M | — | -6.0% |
| Shareholder equity | $45.29M | $78.00M | $92.25M | $16.63M | $34.05M | — | -41.9% |
| Working capital | $84.41M | $100.94M | $109.83M | $36.71M | $56.69M | — | -16.4% |
| Net tangible assets | $44.20M | $76.88M | $91.08M | $15.65M | $33.45M | — | -42.5% |
| Shares issued | 26.43M | 25.83M | 24.12M | 12.11M | 11.66M | — | +2.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$32.65M | -$18.44M | $20.13M | -$21.77M | -$23.52M | — | -77.1% |
| Depreciation & amortisation | $603.00K | $640.00K | $678.00K | $674.00K | $696.00K | — | -5.8% |
| Stock-based compensation | $1.84M | $1.55M | $2.04M | $2.39M | $2.94M | — | +19.0% |
| Change in working capital | $2.63M | -$5.86M | -$27.21M | $1.89M | -$2.62M | — | +144.9% |
| Operating cash flow | -$13.44M | -$11.94M | -$11.25M | -$15.27M | -$20.27M | — | -12.6% |
| Capital expenditure | — | -$118.00K | -$369.00K | — | -$17.00K | -$314.00K | — |
| Investing cash flow | $1.00K | -$114.00K | -$325.00K | $17.00K | -$12.00K | — | +100.9% |
| Financing cash flow | $0 | $745.00K | $77.52M | $1.66M | $5.30M | — | -100.0% |
| Free cash flow | -$13.44M | -$12.05M | -$11.62M | -$15.27M | -$20.29M | — | -11.5% |
| End cash position | $112.41M | $125.85M | $137.15M | $71.21M | $84.81M | — | -10.7% |
Options analytics
Put / call volume
0.00
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
5.00
-19.4% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
-25.0%
Calls bid over puts
Call volume
56
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
5.00
0 contracts
Heaviest put OI
7.50
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.69 | -1.26 | -81.7% |
| Mar 2026 | -0.81 | -0.75 | +7.4% |
| Dec 2025 | -0.64 | 1.01 | +256.4% |
| Sep 2025 | -2.21 | -1.84 | +16.7% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.89 | 3 | $1.38M | +10,476.9% |
| Next quarter | -0.98 | 3 | $1.25M | -96.3% |
| Current year | -3.87 | 3 | $13.48M | -60.7% |
| Next year | -1.86 | 2 | $8.88M | -34.2% |
Analyst targets & ownership
Mean target$29.40
High target$60.00
Low target$18.00
Implied upside374.19%
Analyst count5
ConsensusNONE
Strong buy / Buy0 / 5
Hold0
Sell / Strong sell0 / 0
Held by insiders8.04%
Held by institutions68.71%
Institutions holding134
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
6.27
-1.18% from price
SMA 20
6.58
-5.72% from price
SMA 50
7.24
-14.31% from price
SMA 100
7.30
-15.04% from price
SMA 200
6.33
-2.03% from price
EMA 12
6.41
-3.21% from price
EMA 26
6.74
-7.96% from price
EMA 50
7.03
-11.77% from price
RSI (14)
35.2
Neutral
MACD (12,26,9)
-0.33
Hist 0.00
ATR (14)
0.39
6.33% of price
Realised vol 30D
54.3%
Annualised
Bollinger upper
7.31
20, 2σ
Bollinger lower
5.84
20, 2σ
50 / 200 cross
Golden
7.24 vs 6.33
Trend bias
Below 200
-2.03%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.98
Less volatile than market
Correlation to SPY
0.18
Largely independent
Realised vol 30D
54.3%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-58.5%
Peak to trough
Max drawdown 5Y
-98.9%
Peak to trough
ATR 14
0.39
6.33% of price
Beta (reported)
1.28
5Y monthly, from filing
Short interest
Shares short
2.22M
Prior 2.40M
Change vs prior
-7.4%
Shorts covering
% of float
8.25%
Normal
% of shares out
8.06%
Against total outstanding
Days to cover
8.5
Crowded exit
Float
25.45M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 3, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jul 9, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 9, 26 | Oppenheimer | INITIATED | — | Outperform |
| May 27, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 21, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 28, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 19, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Feb 19, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jan 10, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jan 10, 25 | BMO Capital | UPGRADE | Market Perform | Outperform |
| May 30, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 16, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split1:30
Split dateFeb 14, 2024
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-24
Offering Registrations
S-8 · 2026-08-07
Periodic Financial Reports
10-Q · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-07-27
Corporate Changes & Voting Matters
8-K · 2026-07-01
Corporate Changes & Voting Matters
8-K · 2026-06-16
Corporate Changes & Voting Matters
8-K · 2026-05-27
Corporate Changes & Voting Matters
8-K · 2026-05-26
Headlines
Gene-Editing Powerhouse And Its Rivals Surge Toward A Breakout
Investor's Business Daily · 19d ago
Precision BioSciences Doses First Patient in Trial of Potential Duchenne Muscular Dystrophy Treatment
MT Newswires · 44d ago
Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study
Business Wire · 44d ago
Precision BioSciences: Q2 Earnings Snapshot
Associated Press · 62d ago
Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Business Wire · 62d ago
Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026
Business Wire · 68d ago
Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones
Business Wire · 72d ago
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Business Wire · 89d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.